EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function.
Isshiki Y, Chen X, Teater M, Karagiannidis I, Nam H, Cai W, Meydan C, Xia M, Shen H, Gutierrez J, Easwar Kumar V, Carrasco SE, Ouseph MM, Yamshon S, Martin P, Griess O, Shema E, Porazzi P, Ruella M, Brentjens RJ, Inghirami G, Zappasodi R, Chadburn A, Melnick AM, Béguelin W.
Isshiki Y, et al. Among authors: nam h.
Cancer Cell. 2024 Nov 30:S1535-6108(24)00441-0. doi: 10.1016/j.ccell.2024.11.006. Online ahead of print.
Cancer Cell. 2024.
PMID: 39642889